Levi & Korsinsky Investigating Whether PROCEPT BioRobotics Corporation (PRCT) Misled Investors - Securities Law Violations Possible Ready to Announce with Confidence?
New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into PROCEPT BioRobotics Corporation (NASDAQ: PRCT) ("PROCEPT BioRobotics Corporation") concerning potential violations of the federal securities laws.
On the Q3 2025 earnings call on November 4, 2025, CFO Kevin Waters reaffirmed the $325.5 million revenue target and stated the company was "maintaining handpiece average selling prices to be approximately $3,200." CEO Larry Wood added that investments in strategic priorities were "not expect[ed] ... to impede our progress toward achieving profitability." At the time of these statements, the Company had implemented a pricing-discipline initiative that eliminated historical bulk-purchase discounts -- a change that directly reduced realized average selling prices on the Company's core product line.
The guidance did not quantify or disclose the revenue impact of this pricing change. When Q4 2025 results were released, actual revenue fell $17.4 million short of the guided figure, and FY 2026 guidance of $410 million to $430 million also came in below analyst consensus. The stock lost roughly 15% of its value in a single session.
If you suffered a loss on your PROCEPT BioRobotics Corporation securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288647
Source: Levi & Korsinsky, LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Levi & Korsinsky, LLP or all companies in the Banking / Financial Services industry.
ALIT ALERT: Levi & Korsinsky Investigates Alight, Inc. on Behalf of Shareholders Who Lost Money
2026-03-16 12:29 AM EDT
Levi & Korsinsky Investigating Whether PROCEPT BioRobotics Corporation (PRCT) Misled Investors - Securities Law Violations Possible
2026-03-16 12:27 AM EDT
Lost Money on Gartner, Inc. (IT)? Contact Levi & Korsinsky to Protect Your Rights
2026-03-16 12:24 AM EDT
Aug 22, 2025
" The EDGAR Next deadline is no longer a future concern—it is an immediate compliance requirement. Companies that fail to complete enrollment risk losing filing access at a critical time. " The EDGAR Next deadline is only weeks away. On September 15, 2025, the SEC will switch to its new system, and companies that haven’t completed enrollment risk being unable to file. This article is a practical transition checklist—highlighting what’s changing, the steps to take now, and the last-minute...
Economy, Business and Finance
Legal Service
Litigation and Regulation
Banking / Financial Services